Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 versus erlotinib switching strategy in EGFR-mutant NSCLC with emerging T790M resistance
2015-005637-47Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Switch to osimertinib with Continue erlotinib (2 arms). Primary endpoint: Temporal changes in T790M levels. Started Mar 2017; status: completed.
02
Drugs
osimertiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005637-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005637-47.